Scandion Oncology announced that Richard L. Schilsky, MD, FACP, FSCT, FASCO has accepted to join the clinical advisory board of Scandion Oncology. Dr. Schilsky brings significant experience in medical oncology and will work with medical team and the other members of the CAB to develop Scandion Oncology´s clinical research in quest for resistance modulating cancer drugs. His knowledge and experience will help Scandion Oncology to position and develop the company´s lead compound SCO-101 for the benefit of people with life-threatening treatment resistant cancer. Dr. Schilsky has extensive experience working with both the NCI and the Food and Drug Administration (FDA) having served as a member and chair of the NCI Board of Scientific Advisors, as a member of the NCI Clinical and Translational Research Committee, and as a member and chair of the Oncologic Drugs Advisory Committee of the FDA.